David T. Teachey, MD

faculty photo
Associate Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
Colket Translational Research Building, Room 3008
3501 Civic Center Boulevard
Philadelphia, PA 19104
Office: 2674265802
Fax: 2155903770
BS (Magna cum laude with Honors in Biology)
Virginia Commonwealth University, 1993.
MD (Medicine)
Eastern Virginia Medical School, 1999.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research program focuses on two areas: acute lymphoblastic leukemia and immune dysregulation. My first area of interest centers on development and translation of novel therapies for acute lymphoblastic leukemia (ALL). My lab targets a number of signaling pathways in ALL and also develops and tests novel immunotherapies. I often use xenograft models to study the efficacy of agents and mechanism of action of those agents directly on leukemia cells obtained from children. My laboratory has developed xenografts from over 400 unique patients. This work has led to a number of national and international clinical trials. For many of these trials correlative studies are performed in my laboratory. I hold a number of leadership roles in ALL in the Children's Oncology Group. I am a member of the COG ALL disease steering committee, the leader of the T-ALL clinical trial and biology task force, and Vice Chair for ALL Biology

The other major area of research in my lab centers on improved understanding of immune dysregulation disorders. I study a rare pediatric disorder called autoimmune lymphoproliferative syndrome (ALPS), using preclinical models to study disease biology and translate novel therapies to the clinic. I also study cytokine release syndrome after immunotherapies and hemophagocytic syndromes. More recently, I have studied immune dysregulation after infection with SARS-CoV-2 in children.

Description of Clinical Expertise

My clinical interests include pediatric leukemia and immune dysregulation with emphasis on acute lymphoblastic leukemia, lymphoproliferative disorders, cytokine storm syndromes, and hematopoietic stem cell transplant.

Selected Publications

Diorio C, Henrickson S, Vella L, McNerney K, Chase J, Burudpakdee C, Lee J, Jasen C, Balamuth F, Barrett D, Banwell B, Bernt K, Blatz AM, Chiotos K, Fisher B, Fitzgerald J, Gerber J, Gollomp K, Gray C, Grupp S, Harris R, Kilbaugh T, Odom John A, Lambert MP, Liebling E, Paessler M, Petrosa W, Phillips C, Reilly A, Romberg N, Seif AE, Sesok-Pizzini D, Sullivan K, Vardaro J, Behrens E*, Teachey DT*, Bassiri H*, *equal contribution: MIS-C and COVID-19 are distinct pathophysiologic presentations of SARS-CoV-2. Journal of Clinical Investigation 130(11): 5967-75, November 2020.

Meyer L, Huang BJ, Delgado-Martin C, Roy R, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olsen AB, Wood B, Hortonz T, Shannon K, Teachey DT*, Hermiston ML* (*Equal Contribution): Glucocorticoids paradoxically facilitate steroid resistance in subsets of T-cell acute lymphoblastic leukemia and normal thymocytes. Journal of Clinical Investigation 130(2): 863-876, February 2020.

Teachey DT and O'Connor D: How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 135(3): 159-166, January 2020.

Teachey DT and Pui CH: Comparative features and outcomes between pediatric T-cell and B-cell acute lymphoblastic leukemia. Lancet Oncol 20(3): e142-154, March 2019.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT: Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia Blood 131(9), March 2018 Notes: *Featured Commentary.

Fitzgerald J, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw PA, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT: Cytokine Release Syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Critical Care Medicine 45(2): e124-131, February 2017.

Teachey DT, Lacey SF, Shaw P, Melenhorst J, Maude SL, Frey N, Pequignot E, Gonzalez V, Chen F, Finklestein J, Barrett D, Weiss S, Fitzgerald J, Berg R, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White J, Nazimuddin F, Wertheim G, Levine B, June CH, Porter DL, Grupp SA: Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia Cancer Discovery 6(6): 664-79, June 2016.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood A, Tasian SK, Hunger S, Loh M, Mullighan C, Wood B, Hermiston M, Grupp SA, Lock RB, Teachey DT: Efficacy of Jak/Stat pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood 125(11): 1759-67, March 2015.

Bride KL, Vincent T, Smith-Whitley K, Lamber MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT: Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 127(1): 17-28, January 2016 Notes: *Plenary paper with featured commentary.

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald J, Aplenc R, Gore R, Grupp SA: Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood 121(26): 5154-7, June 2013.

back to top
Last updated: 04/05/2021
The Trustees of the University of Pennsylvania